Bispecific antibodies (bsAb) are emerging as an important class of therapeutics. Bispecific antibodies have increased potential for precision targeting and higher potency. Multi antigen binding can help reduce the development of subsequent clinical resistance. Different strategies have been used in the past to create bsAbs. However, key challenges remain with the developability of bispecific antibodies:
*Lonza internal data
Lonza’s bYlok® platform technology was developed keeping in mind the evolving needs of antibody-drug developers. The simplicity of application is within the design itself. It provides an engineering solution for bispecific antibodies where two different light chains are needed.
By moving the disulphide bridge from constant domains (CH1/CL) to variable domains (VH/VL), the formation of HC-LC heterodimers is favored. The modifications add minimal changes to the molecule’s natural design to minimize unwanted immune responses and support excellent manufacturability.
Access to our bYlok® technology is easy. The technology is available via a simple research license to see if it fits your processes.